RALA

Across TCGA pan-cancer cohorts, RALA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RALA data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RALA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RALA expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where RALA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.942	0.481	.001	33	view →
HNSC	OS	Median	II,III,IV	1.000	0.928	.004	25	view →
LUAD	DFS	Tertile	All	0.594	0.795	.007	24	view →
GBM	DFS	Median	All	0.847	0.643	<.001	18	view →
CCRCC	DFS	Median	II,III,IV	0.451	1.000	.008	11	view →
PDAC	DFS	Tertile	II,III,IV	0.665	0.841	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RALA–LSCC (DFS)

Open the LSCC breakdown →